Alexion, following clues from early tests, preps phase 3 study of Ultomiris in severe COVID-19

As researchers worldwide look for COVID-19 answers, Alexion is starting a phase 3 study of rare disease med Ultomiris. (Alexion)

For about two months, Alexion has been exploring whether its Soliris—used to treat several rare diseases—might hold promise in treating patients with severe COVID-19, the illness caused by the novel coronavirus. But on Monday, the company said it was starting a phase 3 trial of Ultomiris, a similar medicine it launched last year. 

RELATED: Coronavirus tracker: Novartis trial tackles the chloroquine question; NIH, Gilead post new remdesivir animal results

Alexion reached out to federal authorities back in February about the possibility of using Soliris, a drug that inhibits part of the body's immune system, in treating COVID-19 patients who are also suffering from severe pneumonia or acute respiratory distress syndrome. At the time, the company said there was “preclinical scientific rationale” to believe Soliris might be able to help certain COVID-19 patients. By inhibiting the complement portion of a patient's immune system, the drug might play a role in stopping an immune response that actually makes the illness worse, researchers have said.

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

Fast forward to Monday, and Alexion said it’s starting a phase 3 trial of Ultomiris—the follow-up drug to Soliris—in COVID-19 patients with severe pneumonia or acute respiratory distress syndrome. The global trial will enroll about 270 patients.  

In deciding to start the trial, Alexion cited preclinical data that show that the inhibition of terminal complement can lower cytokine and chemokine levels, plus reduce lung inflammation. The company says it knows of ongoing or planned studies by independent investigators, and that early results warrant a controlled clinical test. 

As for the decision to test Ultomiris rather than Soliris, the company says the newer drug is the "future" of its drug class, and that less frequent dosing can lower healthcare burdens. Plus, the company can make the drug at a higher capacity.  

RELATED: Alexion plans phase 2 study of Soliris in COVID-19 in coming days: report 

Meanwhile, a small study of Soliris is examining mortality, time in intensive care and time on a ventilator for patients who receive the medicine, according to info posted on 

"While this virus is the provocateur, it is often the patient's own disproportionate immune response which deals the most devastating (and often fatal) damage," the study summary says. "A specific part of the immune system, known as the complement, has been shown to cause such damage in other types of coronaviruses." 

SPECIAL REPORT: The top 20 pharma companies by 2019 revenue

In starting the new study, Alexion becomes the latest drugmaker to explore whether an existing medicine might be able to help patients with COVID-19. An effective therapy is seen as one key component to being able to reopen economies.

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.